IPO - Profile


We are an early-stage bioscience company that focuses on research, development and commercialization of traditional Chinese medicine for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally. We started in Hong Kong in 2014 with main operation and assets in Hong Kong. We aim to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$9.50 2,300,000 Positive High 41.47%

Offering Team

  • Legal counsel
  • Hunter Taubman Fischer & Li LLC
  • Auditors
  • Friedman LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 16 Jul, 2021

Offer 16 Jul, 2021

Look Ahead

Lock Up Expiry Jan 16, 2022

IPO Terms

Offer Price $9.50
Offer Size 2M

Market Sentiments

Stock Price